索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]缪美琪,韩宇博,邹国良,等.细胞焦亡在冠状动脉粥样硬化中的研究进展[J].国际心血管病杂志,2023,03:144-147.
点击复制

细胞焦亡在冠状动脉粥样硬化中的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2023年03期
页码:
144-147
栏目:
综述
出版日期:
2023-05-30

文章信息/Info

Title:
-
作者:
缪美琪; 韩宇博; 邹国良; 郭东浩; 杜若齐; 刘莉
150040 哈尔滨，黑龙江中医药大学附属第一医院心血管一科
Author(s):
-
关键词:
细胞焦亡; 冠状动脉粥样硬化; 药物靶点; 研究进展
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2023.03.005
文献标识码:
-
摘要:
细胞焦亡是一种新型的炎性程序性细胞死亡，在冠状动脉粥样硬化（CA）过程中时刻存在。炎性反应是先天免疫的主要反应，是引发和驱动CA的必要条件。细胞焦亡可能调节CA的发生发展。许多细胞焦亡的抑制剂可减少心脏炎性反应，细胞焦亡的靶向药物可治疗CA。该文介绍细胞焦亡在CA中的研究进展。
Abstract:
-

参考文献/References

[1]Zhou Y, Zhou H, Hua L, et al. Verification of ferroptosis and pyroptosis and identification of PTGS2 as the hub gene in human coronary artery atherosclerosis[J]. Free Radic Biol Med, 2021, 171:55-68.
[2]Kovacs SB, Miao EA. Gasdermins: effectors of pyroptosis[J]. Trends Cell Biol, 2017, 27(9):673-684.
[3]Zhaolin Z, Guohua L, Shiyuan W, et al. Role of pyroptosis in cardiovascular disease[J]. Cell Prolif, 2019, 52(2):e12563.
[4]Artiach G, Sarajlic P, B?ck M. Inflammation and its resolution in coronary artery disease: a tightrope walk between omega-6 and omega-3 polyunsaturated fatty acids[J]. Kardiol Pol, 2020, 78(2):93-95.
[5]Fang Y, Tian S, Pan Y, et al. Pyroptosis: a new frontier in cancer[J]. Biomed Pharmacother, 2020, 121:109595.
[6]Jorgensen I, Miao EA. Pyroptotic cell death defends against intracellular pathogens[J]. Immunol Rev, 2015, 265(1):130-142.
[7]Liu X, Zhang ZB, Ruan JB, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores[J]. Nature, 2016, 535(7610):153-158.
[8]Wang YP, Gao WQ, Shi XY, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin[J]. Nature, 2017, 547(7661):99-103.
[9]Xu YJ, Zheng L, Hu YW, et al. Pyroptosis and its relationship to atherosclerosis[J]. Clin Chim Acta, 2018, 476:28-37.
[10] 翁秀朱, 贾海波. 细胞焦亡在心血管疾病中作用的研究进展[J]. 中国动脉硬化杂志, 2021, 29(9):807-813.
[11] Zeng ZL, Zheng QP, Chen JJ, et al. FGF21 mitigates atherosclerosis via inhibition of NLRP3 inflammasome-mediated vascular endothelial cells pyroptosis[J]. Exp Cell Res, 2020, 393(2):112108.
[12] Li YY, Niu X, Xu HT, et al. VX-765 attenuates atherosclerosis in ApoE deficient mice by modulating VSMCs pyroptosis[J]. Exp Cell Res, 2020, 389(1):111847.
[13] Lin Y, Liu MH, Chen EQ, et al. Bone marrow-derived mesenchymal stem cells microvesicles stabilize atherosclerotic plaques by inhibiting NLRP3-mediated macrophage pyroptosis[J]. Cell Biol Int, 2021, 45(4):820-830.
[14] Pan JY, Han L, Guo J, et al. AIM2 accelerates the atherosclerotic plaque progressions in ApoE?/? mice[J]. Biochem Biophys Res Commun, 2018, 498(3):487-494.
[15] Shokoples BG, Paradis P, Schiffrin EL. P2X7 receptors:an untapped target for the management of cardiovascular disease[J]. Arterioscler Thromb Vasc Biol, 2021, 41(1):186-199.
[16] Wu J, Cai W, Du R, et al. Sevoflurane alleviates myocardial ischemia reperfusion injury by inhibiting P2X7-NLRP3 mediated pyroptosis[J]. Front Mol Biosci, 2021, 8:768594.
[17] Ji N, Qi ZW, Wang YY, et al. Pyroptosis: a new regulating mechanism in cardiovascular disease[J]. J Inflamm Res, 2021, 14:2647-2666.
[18] 曲宁宁, 宋囡, 贾连群, 等. 化瘀祛痰方对动脉粥样硬化家兔心肌组织细胞焦亡的影响[J]. 中华中医药杂志, 2021, 36(10):6055-6058.
[19] 曹朝晖, 吴颛, 胡小波. 细胞焦亡参与动脉粥样硬化形成的分子机制新进展[J]. 中国动脉硬化杂志, 2021, 29(7):560-565.
[20] Coll RC, Hill JR, Day CJ, et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition[J]. Nat Chem Biol, 2019, 15(6):556-559.
[21] Zeng WY, Wu DB, Sun YX, et al. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages[J]. Sci Rep, 2021, 11(1):19305.
[22] Gao R, Shi H, Chang S, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction[J]. Int Immunopharmacol, 2019, 74:105575.
[23] Liu S, Xu DS, Ma JL, et al. LncRNA H19 mitigates oxidized Low-Density lipoprotein induced pyroptosis via caspase-1 in raw 264.7 cells[J]. Inflammation, 2021, 44(6):2407-2418.
[24] Wang Q, Wu J, Zeng Y, et al. Pyroptosis: a pro-inflammatory type of cell death in cardiovascular disease[J]. Clinica Chimica Acta, 2020, 510:62-72.
[25] Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial[J]. Lancet, 2018, 391(10118):319-328.
[26] Wu LM, Wu SG, Chen F, et al. Atorvastatin inhibits pyroptosis through the lncRNA NEXN-AS1/NEXN pathway in human vascular endothelial cells[J]. Atherosclerosis, 2020, 293:26-34. （收稿：2022-03-13 修回：2023-02-06）

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（82074346）；黑龙江省博士后经费项目（LBH-Z18253）；黑龙江中医药大学校科研基金资目（2019TD01， 2019BS02）
更新日期/Last Update: 2023-05-30